Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 14;12(1):16.
doi: 10.3390/antib12010016.

Bioprocess Development and Characterization of a 13C-Labeled Hybrid Bispecific Antibody Produced in Escherichia coli

Affiliations

Bioprocess Development and Characterization of a 13C-Labeled Hybrid Bispecific Antibody Produced in Escherichia coli

Aaron T Wecksler et al. Antibodies (Basel). .

Abstract

Monoclonal antibodies (mAbs) are highly efficacious therapeutics; however, due to their large, dynamic nature, structural perturbations and regional modifications are often difficult to study. Moreover, the homodimeric, symmetrical nature of mAbs makes it difficult to elucidate which heavy chain (HC)-light chain (LC) pairs are responsible for any structural changes, stability concerns, and/or site-specific modifications. Isotopic labeling is an attractive means for selectively incorporating atoms with known mass differences to enable identification/monitoring using techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR). However, the isotopic incorporation of atoms into proteins is typically incomplete. Here we present a strategy for incorporating 13C-labeling of half antibodies using an Escherichia coli fermentation system. Unlike previous attempts to generate isotopically labeled mAbs, we provide an industry-relevant, high cell density process that yielded >99% 13C-incorporation using 13C-glucose and 13C-celtone. The isotopic incorporation was performed on a half antibody designed with knob-into-hole technology to enable assembly with its native (naturally abundant) counterpart to generate a hybrid bispecific (BsAb) molecule. This work is intended to provide a framework for producing full-length antibodies, of which half are isotopically labeled, in order to study the individual HC-LC pairs.

Keywords: 13C-celtone; 13C-labeled glucose; ambr250 bioreactors; biotherapeutic proteins; knob-into-hole; protein isotopic labeling.

PubMed Disclaimer

Conflict of interest statement

All authors are employees of Genentech at the time of data collection, and the company provided necessary supports and resources in the study. The objectivity and authenticity of the experimental results and discussion were not affected by the company.

Figures

Figure 1
Figure 1
End-of-run growth (A) and initial osmolality (B) of E. coli cultures expressing hAb1 grown in primary inoculum culture media containing tryptone and yeast extract (control), unlabeled Celtone (Celtone), and unlabeled Celtone 2-fold dilution (Celtone 2-fold). Results shown are from n = 1 experiment. Growth (C) and osmolality (D) of E. coli cultures expressing hAb1 grown in production fermentation media containing NZ Soy BL4 and yeast extract (filled circles), unlabeled Celtone (open circles), unlabeled Celtone 2-fold dilution (open triangles), and unlabeled Celtone 4-fold dilution (open diamonds). Results shown are from n = 1 experiment.
Figure 2
Figure 2
Growth (A), osmolality (B), titer (C), and phosphate depletion (D) of E. coli cultures expressing hAb1 grown in production fermentation media containing NZ Soy BL4 and yeast extract (filled circles), unlabeled Celtone 4-fold dilution (filled diamonds), and E. coli cultures expressing hAb2 grown in media containing 13C-labeled Celtone 4-fold dilution (filled squares). Results shown are from n = 1 experiment. Note: 13C-labeled fermentation was terminated at 64 h due to operational challenges.
Figure 3
Figure 3
Intact mass analysis of the hybrid molecule (right side) compared to the predicted WT molecule (left side).

Similar articles

Cited by

References

    1. Lu R.M., Hwang Y.C., Liu I.J., Lee C.C., Tsai H.Z., Li H.J., Wu H.C. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 2020;27:1. doi: 10.1186/s12929-019-0592-z. - DOI - PMC - PubMed
    1. Kaplon H., Chenoweth A., Crescioli S., Reichert J.M. Antibodies to watch in 2022. MAbs. 2022;14:2014296. doi: 10.1080/19420862.2021.2014296. - DOI - PMC - PubMed
    1. Carter P.J., Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185:2789–2805. doi: 10.1016/j.cell.2022.05.029. - DOI - PubMed
    1. Chiu M.L., Goulet D.R., Teplyakov A., Gilliland G.L. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies. 2019;8:55. doi: 10.3390/antib8040055. - DOI - PMC - PubMed
    1. Sevy A.M., Meiler J. Antibodies: Computer-Aided Prediction of Structure and Design of Function. Microbiol. Spectr. 2014;2:173–190. doi: 10.1128/microbiolspec.AID-0024-2014. - DOI - PubMed

LinkOut - more resources